Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: abatacept

Abatacept Shows Promise for Some Myositis Patients

Deborah Levenson  |  May 12, 2025

Injected abatacept may be a worthwhile treatment for certain patients with idiopathic inflammatory myositis (IIM), according to recent research.1 Patients with the rare autoimmune conditions involving inflammation of muscle (myositis) and other organ systems suffer widespread organ dysfunction, increased morbidity, physical disabilities and early death. Symptoms vary by subtype. For example, dermatomyositis (DM) involves muscle…

Filed under:Biologics/DMARDsConditionsDrug UpdatesMyositisResearch ReviewsResearch Rheum Tagged with:abataceptAC&Ridiopathic inflammatory myositis

Upadacitinib Receives Breakthrough Designation, Abatacept Use Expands in Australia & More

Michele B. Kaufman, PharmD, BCGP  |  January 31, 2018

The FDA has designated upadacitinib a breakthrough therapy to treat adults with moderate to severe atopic dermatitis…

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:abataceptAddictionaddiction treatmentbuprenorphineCAM2038Psoriatic ArthritisU.S. Food and Drug Administration (FDA)upadacitinib

Abatacept Approved for Psoriatic Arthritis in Adults; Sirukumab Approval Stalls

Michele B. Kaufman, PharmD, BCGP  |  September 17, 2017

Abatacept Approved for Adult PsA On June 30, the U.S. Food and Drug Administration (FDA) approved abatacept (Orencia) to treat adults with active psoriatic arthritis (PsA).1 Abatacept is available as both an intravenous formulation and a subcutaneous injection.2 The approval was based on results of two randomized, double-blind, placebo-controlled trials, PsA-I and PsA-II, during which…

Filed under:ConditionsDrug UpdatesResearch Rheum Tagged with:apataceptApprovalsClinicaldrugFDAMedicationOrenciaoutcomePsoriatic ArthritisRAResearchRheumatoid arthritisrheumatologySafetysirukumabstudyTreatmenttrial

Abatacept Plus Prednisone Therapy Studied for Treating Giant Cell Arteritis

Linda Childers  |  September 17, 2017

A recent study, conducted by the Vasculitis Clinical Research Consortium and funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), examined whether the addition of abatacept, a drug that affects T cell activation, to standard prednisone treatment could reduce the risk of relapse in patients with giant cell arteritis (GCA).1 Although…

Filed under:ConditionsResearch RheumVasculitis Tagged with:abataceptACR Journal ReviewAmerican College of Rheumatology (ACR)Giant Cell ArteritisGlucocorticoidspatient careprednisonerelapseResearchrheumatologyriskSteroidT celltherapyTreatmentVasculitis

Abatacept Approved for Adult PsA

Michele B. Kaufman, PharmD, BCGP  |  July 31, 2017

The FDA has approved abatacept to treat adults with active psoriatic arthritis. In clinical trials, the treatment has proved effective in both intravenous and subcutaneous forms…

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:abataceptFDAFood and Drug AdministrationPsoriatic ArthritisU.S. Food and Drug Administration

FDA Requests Removal of Opana ER; Plus Abatacept’s New Dosing Option

Michele B. Kaufman, PharmD, BCGP  |  June 21, 2017

The FDA has asked the manufactures of Opana ER to remove the opioid from the U.S. market due to the public health risk of abuse…

Filed under:AnalgesicsBiologics/DMARDsDrug Updates Tagged with:abataceptFDAFood and Drug Administrationjuvenile idiopathic arthritis (JIA)Opana EROpioid abuseOpioidspolyarticular arthritispublic healthSafety

Similar RA Outcomes with Abatacept & Tocilizumab

Will Boggs, MD  |  August 17, 2015

NEW YORK (Reuters Health)—Clinical outcomes of rheumatoid arthritis (RA) are similar with abatacept and tocilizumab treatment, but the factors that predict efficacy differ for the two agents. “The recommendations for RA treatment from the U.S. and EU describe the use of abatacept and tocilizumab as first-line biologics along with anti-TNF (anti-tumor necrosis factor) inhibitors,” Dr….

Filed under:Biologics/DMARDsConditionsDrug UpdatesRheumatoid Arthritis Tagged with:abataceptBiologics & BiosimilarsRheumatiod arthritistocilizumab

Cancer cells

Cancer & RA Drugs: Are Some Drugs Riskier than Others?

Samantha C. Shapiro, MD  |  February 4, 2025

Sendaydiego et al. asked: Do some DMARDs pose a greater cancer risk than others for patients with RA? Here are insights from the study and its clinical implications.

Filed under:ConditionsDrug UpdatesRheumatoid Arthritis

Sunrise, Sunset: A Look Back on the Year in Rheumatology

Jason Liebowitz, MD, FACR  |  December 4, 2024

At the ACR Convergence 2024 Year in Review lecture, experts discussed advancements in disease understanding and treatments, as well as in basic science.

Filed under:ACR ConvergenceConditionsGout and Crystalline ArthritisGuidanceMeeting ReportsOsteoarthritis and Bone DisordersRheumatoid Arthritis Tagged with:ACR Convergence 2024ACR Convergence 2024 goutACR Convergence 2024 RAcardiovascularGoutKnee Osteoarthritis (OA)osteoarthritis (OA)preventionRheumatoid Arthritis (RA)

Top Research in Rheumatoid Arthritis Presented at ACR Convergence 2024

Jeffrey Curtis, MD, MS, MPH  |  December 3, 2024

Why this research is relevant to clinicians today & researchers in the future WASHINGTON, D.C.—The ACR Convergence 2024 meeting in Washington, D.C., reflected the continued advancement of science and practical research in the field of rheumatoid arthritis. Highlights this year centered on new RA treatments and new uses of existing treatments; the use of artificial…

Filed under:ACR ConvergenceConditionsGuidanceMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2024ACR Convergence 2024 RA

  • 1
  • 2
  • 3
  • …
  • 19
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences